Recent Security Class Actions
Allakos Inc. Common Stock (NASDAQ: ALLK)
Company Name:Allakos Inc. Common Stock
Stock Symbol:NASDAQ: ALLK
Class Period Start:03/14/2019
Class Period End (inclusive):12/17/2019
Filing Deadline:05/09/2020
According to the Complaint, Allakos Inc. is a clinical stage biopharmaceutical company that focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The Company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
